Scienza e Tecnologia
EU selects Tada Medical to boost investment into the healthcare sector
"
This investment will help them in scaling up production and accelerating the way to market. Tada Medical has come a long way, receiving patents in several countries and a CE mark on its first-generation breakaway connector, ReLink Care . The company's Quality Management System is ISO 13485 certified and new developments will open many doors in the global market. Their commercialisation plan is to expand and sign licencing agreements with key players in the IV therapy market. Tada Medical has embarked on an amazing journey, a journey that not only solves unmet clinical needs but also spurs growth and improvement. A journey of striving for excellence and creating evidence for commercialization. The team is proud of their ground-breaking innovation and humbly thank the network and friends they have met along this journey who are part of their success.
Tada Medical AB is a Swedish medical device company specialising in needs-based innovations for health and medical care. Our vision is to improve lives by providing innovative solutions for unmet healthcare needs. IV therapy is the most frequent invasive procedure in modern healthcare, being received by 90% of in-hospital patients. Unfortunately, on average 46% of these procedures will be prematurely interrupted by mechanical complications like phlebitis, infiltration and accidental dislodgement where the IV catheter is forcefully ripped from the patient's vein. This results in patient injury, spilled medication, air embolisms and increased workload for the healthcare professionals. It also increases the healthcare professional's risk of exposure to potentially contaminated blood and hazardous drugs. When the problem is that something breaks the standard solution is to make it stronger, we did the opposite - we made it weaker. Our solution to the global healthcare problem of accidental IV dislodgement is our breakaway connector ReLink. ReLink is specially engineered to enhance infusion stability by keeping the connections between patient and IV catheter, with a controlled break away and predictable results, thereby providing increased safety for patients and nurses across the globe.
Established in June 2020 , the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500.000 and €15 million) in European high impact and deep tech start-ups and scale ups. With a long-term perspective, the EIC Fund invests in companies from any sector, across all EU member states as well as in associated countries.
The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialization of disruptive technologies. This is achieved by crowding-in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.
The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.
Rakshita Singh
+46764411753
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/tada-medical-ab/r/eu-selects-tada-medical-to-boost-investment-into-the-healthcare-sector,c3443718
The following files are available for download: